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of the Creative Com
provided it is propeObjective: To examine the effect of selenium supplementation on CD4þ T-cell counts,
viral suppression, and time to antiretroviral therapy (ART) initiation in ART-naive HIV-
infected patients in Rwanda.
Methods: Amulticenter, double-blinded, placebo-controlled, randomized clinical trial
was conducted. Eligible patients were HIV-infected adults (21 years) who had a CD4þ
cell count between 400 and 650 cells/ml (ART eligibility was 350 cells/ml throughout
the trial), and were willing to practice barrier methods of birth control. Patients were
randomized to receive once-daily 200mg selenium tablets or identical placebo. They
were followed for 24 months with assessments every 6 months. Declines in CD4þ cell
counts were modeled using linear regressions with generalized estimating equations
and effect modification, and the composite outcome (ART eligible or ART initiation)
using Cox proportional-hazards regression, both conducted with intention to treat.
Results: Of the 300 participants, 149 received selenium, 202 (67%) were women, and
median age was 33.5 years. The rate of CD4þ depletion was reduced by 43.8% [95%
confidence interval (CI) 7.8–79.8% decrease] in the treatment arm – from mean
3.97cells/ml per month to mean 2.23cells/ml per month. We observed 96 composite
outcome events – 45 (47%) in the treatment arm. We found no treatment effect for the
compositeoutcome (hazard ratio1.00, 95%CI0.66–1.54) or viral suppression (odds ratio
1.18,95%CI0.71–1.94). The trialwasunderpowered for the compositeoutcomedue toa
lower-than-anticipated event rate. Adverse events were comparable throughout.
Conclusions: This randomized clinical trial demonstrated that 24-month selenium
supplementation significantly reduces the rate of CD4þ cell count decline among
ART-naive patients. Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2015, 29:1045–1052Keywords: CD4þ cells, HIV/AIDS, randomized clinical trial, selenium Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
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HIV infection compromises the nutritional status of the
infected individuals, and poor nutritional status can
accelerate progression of the disease [1]. The relationship
between immune function and nutritional supplement-
ation has been well described [2–5]. Studies have
reported high rates of nutrient deficiencies early in the
course of HIV infection [6–8].
Among HIV-infected persons not receiving antiretroviral
therapy (ART), observational studies have shown that low
or deficient serum concentrations of several micronu-
trients, including the trace mineral selenium, are
associated with low CD4þ T-cell counts, advanced
HIV-related diseases, faster disease progression, or HIV-
related mortality [9–23]. Selenium is incorporated into a
number of biologically active selenoproteins and is an
essential element of glutathione peroxide (GPX), which
plays an important role in endogenous antioxidant
defense [24,25]. Selenium is also an essential factor in
maintaining host immune competence, and it has been
shown that optimal levels decrease the host’s susceptibility
to viral pathogenesis [26–30]. Selenium deficiency, as
indicated by low plasma selenium concentrations, is
common in HIV-infected individuals [31,32], particularly
in areas of the world with low selenium levels in the soil,
as is true in many regions of sub-Saharan Africa [33–35].
Evidence of the effect of selenium supplementation from
clinical trials is limited in both developed and developing
countries. Three randomized clinical trials (RCTs) have
been conducted to assess the individual association of
selenium supplementation on HIV viral load and CD4þ
T-cell count [36–38]. The first trial, conducted in Miami
by Hurwitz et al. [37], found that selenium supplement-
ation of 200mg daily significantly suppressed the
progression of HIV viral burden and indirectly improved
CD4þ T-cell count after 9 months of treatment. The
second trial, conducted in Tanzania by Kupka et al. [38],
found that selenium supplementation of 200mg daily
provided to HIV-infected pregnant women before and
after pregnancy (between 12 and 27 weeks of gestation
and 6 months after birth) had no significant effect on HIV
viral load or CD4þ T-cell count, but did significantly
lower the risk of infant death. A third trial, a factorial
design by Baum et al. [36] in Botswana, found no
significant effect of selenium supplementation on the rate
of depletion to 200 cells/ml among patients starting with a
CD4þ T-cell count above 350 cells/ml. The authors did,
however, find a significant event rate decrease when
combined with multivitamins [36].
It is important to recognize the inherent differences in
their design, setting, and populations of these trials when
drawing inferences. Additional evidence from other
settings and populations is required to more accurately
determine the effect of selenium supplementation on Copyright © 2015 Wolters Kluwer HHIV progression in HIV-infected individuals. Therefore,
we conducted an RCT to examine the effect of selenium
supplementation on CD4þ T-cell counts, viral suppres-
sion, and time to ART initiation in HIV-infected patients
who are not yet on ART. We conducted our trial
in Rwanda.Methods
The present study is a 24-month, multicenter, patient and
provider-blinded, randomized, placebo-controlled
clinical trial, involving 300 pre-ART HIV-infected
patients in Rwanda. We a priori calculated our sample
size by assuming a 20% reduction in CD4þ T-cell count
depletion. This trial has been registered with Clinical-
Trials.gov under the registration number NCT01327755.
Patients were recruited at two health facilities that offer
care and treatment for HIV/AIDS patients in Rwanda.
These facilities were chosen due to the feasibility of
recruiting all patients within a short period and the
feasibility of coordination. Patient eligibility was
restricted to: HIV-infected adults (21 years of age and
older at study enrollment), who were not yet ART-
eligible based on Rwanda guidelines for ART initiation,
had a CD4þ T-cell count between 400 and 650 cells/ml,
were willing to practice barrier methods of birth control
at all times, and be able to provide written informed
consent. The CD4þ cell count at baseline was
considerably above the Rwanda guidelines for initiation
of ART (350 cells/ml as of 2012). Eligible patients were
identified from pre-ART registers. Participants were
enrolled and followed for 2 years. Study assessments
occurred at baseline, 6, 12, 18, and 24 months.
Patients were excluded if they intended on transferring
out of the clinic catchment area before the study ended
and/or if they were scheduled to start ART. Patients with
psychiatric health concerns and pregnant women were
also excluded.
Randomization
The randomization flowchart is shown in Fig. 1. Partici-
pants were randomized using a simple randomized block
design to receive either seleniumor an identicallyappearing
placebo to be taken once daily for 24 months. The research
department of the treatment supplier prepared the
randomization schedule. Study participants were identified
by unique study identification numbers and were assigned a
specific allocation number. An unblinded list was provided
to the treatmentproviderand to the independent statistician
for the drug safety monitoring board.
Intervention
The trial intervention consisted of once-daily tablets
containing 200mg of selenium in the form of seleno-ealth, Inc. All rights reserved.
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2680 participants screened for study
participation
300 participants eligible and
randomized
149 randomized to receive placebo 151 randomized to receive selenium
2380 participants excluded
9 lost to follow-up
15 pregnancies
•  7 experienced composite
   outcome prior to pregnancy
•  5 moved away
•  1 died (myocardial infraction)
•  3   other reasons
20 refused to use barrier methods
of birth control
79 refused to participate in the
study
290 pregnant at baseline
1354 already on ART
289 aged < 21 years
348 CD4+ < 400 cells/µl
9 lost to follow-up
18 pregnancies
•  3 experienced composite
   outcome prior to pregnancy
•  4 moved away
•  1 died (assault)
•  4 other reasons
•  6 lost to follow-up prior to
     providing follow-up data
143 included in primary analysis
•  4 lost to follow-up prior to
     providing follow-up data
147 included in primary analysis
Fig. 1. Randomization flowchart.methionine containing selenium yeast. The control arm
received an identical placebo. To ensure optimal
adherence, participants received adherence counseling
at baseline and when picking up refills on a monthly basis.
Additional adherence counseling was provided to patients
who had sub-optimal adherence.
The Rwandan Ministry of Health recommends the use of
cotrimoxazole – a sulfonamide antibiotic combination of
trimethoprium and sulfamethoxazole used for the
treatment of a variety of bacterial infections – for all
HIV-infected patients. Therefore, all participants also
received cotrimoxazole, irrespective of experimental
assignment. Participants who did not return to the clinic
as scheduled were followed up at home and received
optimal adherence counseling.
Outcomes and study measures
The primary outcome measures for this study was change
in CD4þ T-cell counts, and a composite of CD4þ T-cell
depletion to 350 cells/ml (as confirmed by two consecu-
tive measures), or start of ART, or the emergence of a
documented CDCþ-defined AIDS-defining illness. For
analyses of the CD4þ T-cell count changes, patients were
censored after ART initiation. Women who initiated
ART through prevention of mother-to-child trans-
mission programs prior to reaching other endpoints the
composite outcome were censored at time of pregnancy
because pregnancy is a mechanism by which ART is
initiated independent of immunological failure. Copyright © 2015 Wolters KluweSecondary outcomes included: viral suppression;
mortality; and adverse events. This study used the
standard level of expedited adverse event reporting as
defined in the Division of AIDS (DAIDS) of the National
Institute of Allergy and Infectious Diseases (NIAID)
Manual for Expedited Reporting of Adverse Events
(Version 2.0, January 2010). Adverse event follow-up was
reported on a standardized form during the protocol-
defined reporting period. After the end of the protocol-
defined adverse event-reporting period, sites were asked
to report serious, unexpected, clinical suspected adverse
drug reactions or if the study site staff becomes aware of
the event on a passive basis (e.g. from publicly available
information).
Trained nurses used structured questionnaires to collect
data on patient demographics at baseline. Additionally, at
baseline and at each follow-up visit, a questionnaire was
used to collect information on psychosocial factors, access
to care and treatment, attitudes towards and experiences
with the supplementation, quality of life, self-efficacy,
nutrition, opportunistic infections, and adherence to the
study protocol. The questionnaire was available in both
English and Kinyarwanda. Nurses also collected clinical
data at baseline and at each follow-up visit, including
information on height, weight, and blood.
Analysis
Baseline demographic and clinical characteristics were
tabulated and compared using Fisher’s exact test forr Health, Inc. All rights reserved.
1048 AIDS 2015, Vol 29 No 9dichotomous outcomes and Wilcoxon’s rank-sum test for
continuous outcomes. Statistical significance was assessed
at the two-sided 5% level unless otherwise indicated. All
analyses were based on the intention-to-treat (ITT)
approach using the randomized treatment assignment. All
available data were used and missing data were removed.
To examine the effect of selenium supplementation on
CD4þ T-cell decay, we used linear regression to model
change from baseline (i.e. all patients were assigned a
change of 0 at baseline). The model included both time in
study and treatment group, with an effect modification on
time-by-treatment group. Generalized estimating
equations (GEEs) were used to account for the
repeated-measures nature of the data. Assumptions for
linear regression, including homogeneity and normality
of residuals, were assessed graphically and met.
Both time-to-event analyses and simpler contingency table
analyses were used to determine whether selenium
supplementation could delay the initiation of ART.
Survival analysis was carried out by way of Cox
proportional-hazards and Kaplan–Meier curves. Only
two models were considered. The first was a simple model
by which the only explanatory variable was treatment, and
the second was an explanatory model with the addition of
self-reported adherence to treatment (measured as all pills
taken). As self-reported adherencewas measuredover time,
we used it as a time-varying covariate. Moreover, we used
baseline CD4þ, age, sex, viral load, and other measures of
adherence to generate multiple imputations to overcome
the missingness in the adherence. These analyses were then
repeated for unadjusted events (a single CD4þ cell count
event). All conditions for survival analysis were verified
using tests based on the Schoenfeld residuals and all
assumptions were met.
For this secondary outcome of viral load, we considered
observed suppression as a measured viral load less than
20 copies/ml. Missing viral loads were considered ‘not
observed as suppressed’ (missing equals failure). Viral
loads were measured at three time points: baseline,
12 months, and 24 months. Given that there were only
two follow-up points, logistic regression was favored over
survival analysis. As such, we used GEEs to account for
repeated measurements on the same individual. Finally,
we removed observation following ART initiation, as this
would clearly interfere with the effects of selenium
supplementation on viral suppression. Two models were
fit – one with only treatment as a predictor and the other
with time of measurement.
All analyses were conducted in SAS 9.3 (Cary, North
Carolina, USA) and in R version 3.0.2 (Vienna, Austria).
Ethics
The present trial received approval from the institutional
review boards of the Canadian College of Naturopathic Copyright © 2015 Wolters Kluwer HMedicine and Wilfred Laurier University in Canada, and
the National Ethics Committee (NEC) in Rwanda.Results
Between September 2010 and January 2011, 300 patients
were identified as eligible and randomized in this study.
The study was conducted between January 2011 and June
2014 (24 months follow-up). Figure 1 shows the
randomization, loss to follow-up, and censoring due to
pregnancy over the study period. Selenium supplements
were provided to 151 participants. Over the 24-month
study period, 18 patients were lost to follow-up – nine
within 6 months of study initiation, four more between 6
and 12 months into the study, three more in the next 6-
month period, and finally two in the final 6 months.
Reasons for loss to follow-up included accidental death,
moving outside the study area, and unknown. The loss to
follow-up counts did not include women who became
pregnant and initiated ART through prevention of
mother-to-child transmission programs. Pregnancy was
nonetheless used as a censoring mechanism. Only two
deaths were experienced, one in each arm, and neither
appeared to be treatment-related.
Table 1 presents baseline characteristics of the study
participants. There were 202 (67%) women, and the
median age among participants was 33.5 years. The
median baseline CD4þ cell count was 540 cells/ml with
an interquartile range (IQR) from 468 to 627 cells/ml.
The base 10 logarithm of viral load at baseline was 3.87
(IQR 3.15–4.45). In total, 84 (28%) patients reported not
using barrier methods of birth control, which explains the
33 pregnancies observed over the 24-month study period.
The duration of follow-up was 24 months for all but
19 patients.
Changes in CD4þ T-cell counts were heterogeneous,
with a SD of 120.3 cells/ml. Table 2 summarizes the linear
regression with GEEs used to model change in CD4þ
according to the treatment group. The average rate of
CD4þ decline among patients using placebo was
3.97 cells/ml per month [95% confidence interval (CI)
3.03, 4.91]. The rate of CD4þ decline was reduced by
43.8% (95% CI 7.8–79.8) among patients using selenium
supplementation. Figure 2 presents the estimated
regression lines for each treatment group and suggests a
difference of approximately 40 cells in decline at the end
of the study period in favor of the treatment group over
the placebo group.
For the composite endpoint, a total of 86 events were
observed after censoring for pregnancy (Table 3). None
of the outcomes were an AIDS-defining illness. Most
were CD4þ cell count depletion to below 350 cells/ml.
Slightly more events occurred in the treatment groupealth, Inc. All rights reserved.
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Sex Male 98 44 (29.1%) 54 (36.2%) 0.151
Female 202 107 (70.9%) 95 (63.8%)
Age 300 33.0 (28.0–39.0) 35.0 (28.0–41.0) 0.418
Marital status Married or living
with partner
180 90 (60.8%) 90 (60.4%) 0.916
Single 26 15 (10.1%) 11 (7.4%)
Widowed 32 15 (10.1%) 17 (11.4%)
Separated 41 19 (12.8%) 22 (14.8%)
Divorced 18 9 (6.1%) 9 (6%)
Employment No 132 65 (43.3%) 67 (45.3%) 0.585
Yes 165 84 (56%) 81 (54.7%)
Refused 1 1 (0.7%) 0 (0%)
BMI at baseline 266 21.5 (19.8–23.7) 21.6 (20.0–24.3) 0.379
CD4þ at baseline 300 552 (470–636) 527 (465–610) 0.126
Viral load (log of) 268 3.8 (3.0–4.5) 3.9 (3.3–4.4) 0.324
Has had sex in past month No 110 50 (33.3%) 60 (40.3%) 0.214
Yes 189 100 (66.7%) 89 (59.7%)
Number of partners in past 30 days NA (skipped) 110 50 (33.3%) 60 (40.5%) 0.390
1 185 98 (65.3%) 87 (58.8%)
2 3 2 (1.3%) 1 (0.7%)
Condom use in past 30 days NA (skipped) 110 50 (33.3%) 60 (40.5%) 0.233
Always 104 59 (39.3%) 45 (30.4%)
Sometimes 30 12 (8%) 18 (12.2%)
Never 54 29 (19.3%) 25 (16.9%)

















20(51.2%), leading to a Fisher’s exact P value of 0.899.
When the definition of the composite outcome was
relaxed to single measurement below 350 cells/ml, to
account for missing second CD4þ measurements, a total
of 115 composite outcomes were observed and 52
(45.2%) occurred in the selenium group. However, this
comparison was also not statistically significant, with a
Fisher’s exact P value of 0.192. Figure 3 shows the
Kaplan–Meier estimates for reaching the composite
endpoint. Table 4 shows the results of the Cox
proportional-hazards regressions. In the analysis using
the two consecutive low CD4þ measurements in the
composite outcome, the hazard ratio comparing the
treatment group to the placebo group was 1.00 (95% CI
0.66–1.53). The result was consistent when accounting
for adherence. The sensitivity analysis using a relaxed
definition for the CD4þ event led to similar results, but
with a lower estimate hazard ratio (0.93) and a larger
hazard ratio for being nonadherent.
For the secondary outcome of viral suppression, the effect
of treatment in the unadjusted model was an odds ratio Copyright © 2015 Wolters Kluwe
Table 2. Linear regression with generalized estimating equations.
Variable
Average CD4þ change
(95% confidence interval) P value
Treatment
Active vs. placebo 4.37 (13.78, 5.04) 0.363
Time (per month) 3.97 (4.91, 3.03) <0.001
Time adjustment
Active vs. placebo 1.74 (0.31, 3.17) 0.017(OR) of 1.18 (95% CI 0.71–1.93) in favor of selenium.
During the trial, the only serious adverse event (SAE)
reported was a myocardial infarction, resulting in death in
the treatment group. There was no evidence to suggest
that this SAE was directly related to the treatment. With
respect to the self-reported adverse events collected at
every 6 months, there was minimal evidence of statistical
differences between the treatment groups. The com-
parisons across treatment groups are presented in Table
A1 (Supplemental Digital Content 1, http://links.lww.
com/QAD/A679) of the ‘Web Appendix’. Patients
taking the placebo were more likely to be anxious
(P¼ 0.035). Patients taking selenium supplementation
were more likely to report that sleep symptoms bothered

















Time (months) on treatment
Active
Placebo
5 10 15 20 25
Fig. 2. Rate of CD4R T-cell count decline across treatment
groups.
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Table 3. Contingency tables for composite outcome.
Treatment Total No Yes P value
Composite outcome
Active 151 107 (50%) 44 (51.2%) 0.899
Placebo 149 107 (50%) 42 (48.8%)
Total (n) 300 214 86
Use only a single CD4þ measurement below 350 as event
Active 151 99 (53.5%) 52 (45.2%) 0.192
Placebo 149 86 (46.5%) 63 (54.8%)
Total (n) 300 185 115little (P¼ 0.011). Both groups reported having no
symptoms, with approximately equal probability. When
adjusting for multiple testing, none of these results were
statistically significant at the 0.05 significance level.
Overall, selenium and placebo supplements were very
well tolerated, helping explain the high percentage of
study completers.Discussion
The present RCT on selenium supplementation in pre-
ART HIV-positive patients in Rwanda provides evidence
of the benefits of selenium supplementation with respect
to reduced rates of CD4þ declines. Our study found a
significant decrease in CD4þ depletion rates, but not on
the combined composite events, including reaching a
CD4þ point of less than 350 cells/ml, AIDS-defining
illness, or death.
Our study has strengths and limitations. The strengths
include our recruitment of patients with higher CD4þ
levels than previous trials that provide evidence for

































Time (months) on treatment
18 24
Fig. 3. Kaplan–Meier plot of time to composite outcome
results.antiretrovirals. Moreover, we monitored adherence and
high retention rate as a result of a strong commitment to
the study on the part of the site nurses. Limitations
include that the event rate for the composite outcome was
much lower than the 60% used for our power
calculations. This resulted in an underpowered analysis
for this outcome. Moreover, only eight women were
censored due to pregnancy in the placebo group
compared to 15 in the treatment group. This unbalanced
censoring may have biased the results in favor of the
placebo treatment. This was the only observed factor by
which the treatment groups differed following random-
ization. The different rates of censoring are not believed
to have affected the CD4þ and viral load analyses.
Although the Miami trial provided strong evidence for
suppression of viral burden and an indirect improvement of
CD4þ, Ross et al. [39] pointed out that these sub-analyses
did not retain the original randomized treatment
allocation. As such, these findings may be subject to bias
not identified by Hurwitz et al. Particularly, analyses were
performed in which participants in the selenium group
who showed a large increase in serum selenium
concentration (’selenium responders’: defined as a change
in serum selenium concentration between baseline and 9
months of above 3 SDs more than the mean change in the
placebo group) were compared with ‘selenium nonre-
sponders’ and with those allocated to placebo. Our findings
were most closely observed in the Botswana trial, where
selenium supplementation was shown to significantly
reduce CD4þ decline, but with no impact on viral burden.
The outcome of this study provides further evidence of
the benefit of low-cost micronutrient supplementation to
HIV-positive patients. This is particularly important for
patients living in resource-limited settings such as much
of Africa. Although assistance has been received from
international funding agencies in order to make the
antiretroviral drugs available for widespread distribution
and treatment of HIV/AIDS patients, it is still a major
financial burden to these countries. This financial burden
is compounded by escalating healthcare costs associated
with a rise in noncommunicable diseases [33,40]. In a
period of worldwide financial uncertainty, any low-costealth, Inc. All rights reserved.









Active vs. placebo 1.00 (0.66–1.53) 0.93 (0.66–1.31)
Adjusted model
Active vs. placebo 1.00 (0.66–1.54) 0.94 (0.66–1.33)
Less-adherent
vs. adherent
1.17 (0.70–1.96) 1.31 (0.85–2.02)
CI, confidence interval.
aThis represents a sensitivity analysis by which a CD4þ event only
required a single CD4þ below 350 cells/ml.
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prior to the requirement for pharmacological interven-
tion should be welcomed.
A growing concern in the treatment of HIV/AIDS in
sub-Saharan Africa is the increase in drug resistance
among those being treated for HIV/AIDS, particularly in
regions where there had been an early roll out of ART
[41]. A delay in progression of the disease brought about
by low-cost micronutrient supplementation would be
advantageous in modifying the rate of drug resistance at
least at the level of the individual.
The HIV disease burden in sub-Saharan Africa is still
important, in terms of incidence, social impact, and
healthcare costs. On the basis of the outcome of this study,
micronutrient supplementation with the trace mineral
selenium may be something to consider in the overall
treatment plan for HIV-positive patients in the pre-ART
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